(Q38170504)

30 August 2017

Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy? (English)

1 reference

30 August 2017

1 reference

1 reference

F-K F Cheng

1

1 reference

30 August 2017

D M Torres

series ordinal

2

1 reference

30 August 2017

S A Harrison

series ordinal

3

1 reference

30 August 2017

language of work or name

1 reference

6 October 2013

1 reference

Journal of Viral Hepatitis

30 August 2017

1 reference

30 August 2017

21

1 reference

30 August 2017

1

1 reference

30 August 2017

1-8

1 reference

Discovery of the hepatitis C virus

30 August 2017

1 reference

STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?

21 January 2018

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

Metabolic alterations and chronic hepatitis C: treatment strategies

21 January 2018

1 reference

Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy

21 January 2018

1 reference

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy.

21 January 2018

1 reference

The evolving role of leptin and adiponectin in chronic liver diseases

21 January 2018

1 reference

Adiponectin and its receptors in patients with chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C virus particles and lipoprotein metabolism.

21 January 2018

1 reference

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

21 January 2018

1 reference

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

21 January 2018

1 reference

Mouse models for the study of HCV infection and virus–host interactions

21 January 2018

1 reference

Hepatitis C virus cell entry: role of lipoproteins and cellular receptors

21 January 2018

1 reference

Hepatitis C virus and host cell lipids: an intimate connection

21 January 2018

1 reference

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

21 January 2018

1 reference

Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion

21 January 2018

1 reference

Hepatitis C core protein impairs insulin downstream signalling and regulatory role of IGFBP-1 expression

21 January 2018

1 reference

Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: comparison between different genotypes and core protein sequence analysis

21 January 2018

1 reference

Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production

21 January 2018

1 reference

Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein

21 January 2018

1 reference

Hepatitis C virus diversity and hepatic steatosis

21 January 2018

1 reference

Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection

21 January 2018

1 reference

HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma

21 January 2018

1 reference

Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core

21 January 2018

1 reference

Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets.

21 January 2018

1 reference

Impact of steatosis on progression of fibrosis in patients with mild hepatitis C.

21 January 2018

1 reference

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

21 January 2018

1 reference

The impact of hepatic steatosis on the natural history of chronic hepatitis C infection

21 January 2018

1 reference

Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial

21 January 2018

1 reference

Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study

21 January 2018

1 reference

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

21 January 2018

1 reference

Hepatitis C virus infection and incident type 2 diabetes

21 January 2018

1 reference

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

21 January 2018

1 reference

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

Hepatitis C and steatosis: a reappraisal

21 January 2018

1 reference

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

21 January 2018

1 reference

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

21 January 2018

1 reference

Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection

21 January 2018

1 reference

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.

21 January 2018

1 reference

Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR.

21 January 2018

1 reference

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

21 January 2018

1 reference

Free fatty acids induce ER stress and block antiviral activity of interferon alpha against hepatitis C virus in cell culture

21 January 2018

1 reference

Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).

21 January 2018

1 reference

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

21 January 2018

1 reference

Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C

21 January 2018

1 reference

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin

21 January 2018

1 reference

Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.

21 January 2018

1 reference

Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin

21 January 2018

1 reference

Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin

21 January 2018

1 reference

Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance

21 January 2018

1 reference

Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy

21 January 2018

1 reference

The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus.

21 January 2018

1 reference

Different anti-HCV profiles of statins and their potential for combination therapy with interferon

21 January 2018

1 reference

Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation

21 January 2018

1 reference

Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids

21 January 2018

1 reference

Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial

21 January 2018

1 reference

Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients

21 January 2018

1 reference

HCV and the hepatic lipid pathway as a potential treatment target

21 January 2018

1 reference

Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C.

21 January 2018

1 reference

Fluvastatin inhibits hepatitis C replication in humans

21 January 2018

1 reference

An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.

21 January 2018

1 reference

An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin

21 January 2018

1 reference

Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis

21 January 2018

1 reference

Review and management of drug interactions with boceprevir and telaprevir

21 January 2018

1 reference

Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin

21 January 2018

1 reference

Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JVH.12172

1 reference

30 August 2017

1 reference